Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.41 |
| ▸ | F2R | P25116 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688835 | 0.85 | F2R (0.40) | SLC2A1PAX8F2RDHFR | |
| SCHEMBL4691146 | 0.83 | SLC2A1 (0.43) | SLC2A1F2RDHFR | |
| SCHEMBL4693852 | 0.83 | F2R (0.47) | SLC2A1F2RDHFR | |
| SCHEMBL4746831 | 0.82 | SLC2A1 (0.64) | SLC2A1F2RDHFR | |
| SCHEMBL5773430 | 0.80 | CSNK2A2 (0.43) | SLC2A1PAX8F2R | |
| SCHEMBL4694078 | 0.79 | KDM4E (0.42) | SLC2A1PAX8F2R | |
| SCHEMBL4687879 | 0.79 | SLC2A1 (0.44) | SLC2A1F2RDHFR | |
| SCHEMBL4689868 | 0.77 | SLC2A1 (0.41) | SLC2A1PAX8 | |
| SCHEMBL4688845 | 0.76 | SLC2A1 (0.48) | SLC2A1PAX8F2RDHFR | |
| SCHEMBL4688232 | 0.76 | DHFR (0.57) | SLC2A1F2RDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| CN-100344629-C | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | CN | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| CN-1791603-A | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTP4A2 | SLC2A1 271/4885PAX8 1715/4885F2R 3381/4885 |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | SLC2A1 298/4885PAX8 2586/4885F2R 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.